MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Veradermics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$122.28+13.46 (+12.37%)
Close on Oct 19, 2026
- Market cap
- $4.94B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 27, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
Press releases
Announcements Veradermics filed with the SEC
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Results of operations · EX-99.1 to Form 8-K
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Study ‘207’ Phase 2 Topline Open Label Data in Females with Mild-to-Moderate Pattern Hair Loss July 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Veradermics Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Study 302 Phase 2/3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss April 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Results of operations · EX-99.1 to Form 8-K